Skip to main content
Clinical Trials/NCT03928964
NCT03928964
Unknown
Not Applicable

Pronostic Assessment of Mortality Among Locally Advanced or Metastatic Renal Cell Carcinoma Patients After First Line Treatment : Multicenter Prospective Cohort Study With Historic Medical Data

Centre Hospitalier Universitaire de Besancon8 sites in 1 country440 target enrollmentJanuary 15, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Renal Cell Carcinoma
Sponsor
Centre Hospitalier Universitaire de Besancon
Enrollment
440
Locations
8
Primary Endpoint
Overall survival after the first line of treatment
Last Updated
7 years ago

Overview

Brief Summary

The hypothesis of this study are as follows:

  • Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
  • In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.
  • The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.
Registry
clinicaltrials.gov
Start Date
January 15, 2018
End Date
April 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Overall survival after the first line of treatment

Time Frame: year 11

Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.

Study Sites (8)

Loading locations...

Similar Trials